from the binomial analysis. For each protein, we then calculated the probability that the imbalance between the numbers of samples showing up-and downregulation would be the same as or more extreme than the imbalance actually observed under the null hypothesis that change direction is completely random (p = 0.5). These imbalance probabilities were taken as the p values of our binomial tests. We then used the Benjamini-Hochberg method 5 to adjust for multiple hypothesis testing and estimated adjusted p values. Imbalances for which the adjusted p value was below 0.05 were considered to be significant.
To identify the single-inhibitor-induced specific apoptosis that was significantly affected by stroma, we grouped the treated samples based on the difference in apoptosis between treated samples in co-culture and those in monoculture. In group I (inhibitor-insensitive samples), the difference in apoptosis in treated samples in co-culture and those in monoculture was less than or equal to −2%; in group II, the difference was between −2% and 2%; and in group III (inhibitorsensitive samples), the difference was 2% or greater. We applied a two-tailed paired Student t test to compare apoptosis with and without stroma in each group. We also used a two-tailed unequal variance Student t test to compare the difference in protein expression between untreated samples in groups I and III with and without stroma and to compare baseline protein expression between untreated samples in groups I and III in co-culture. Statistical significance was defined as p ≤ 0.05.
To identify the co-treatment-induced specific apoptosis that was significantly affected by stroma, we grouped the samples based on the difference in apoptosis between samples treated with single-inhibitor ABT737 or Nutlin-3a and those treated with the dual inhibitors of temsirolimus plus ABT737 or Nutlin-3a in co-culture. In group I, the difference in apoptosis between samples treated with ABT737 or Nutlin-3a alone and those treated with two inhibitors was less than or equal to -2%; in group II, the difference was between −2% and 2% (note: none of the samples fell within the range designated by group II); and in group III, the difference was 2% or greater. The difference in apoptosis between combined-treatment and single-treatment in groups I and III was calculated using a two-tailed paired Student t test. Statistical significance was defined as p ≤ 0.05.
SUPPLEMENTAL FIGURES
Supplemental Figure 1 . RPPA profiling of key proteins in multiple signaling pathways in AML. RPPA was used to profile 53 proteins in 11 signaling pathways involved in cell survival. In the figure, each pathway is surrounded by a blue dashed line. The profiled protein is represented by a color-filled circle with a solid border (total protein) or a broken border (phosphorylated protein). The bar graph on the left displays specific apoptosis for samples treated with ABT737 in monoculture and stromal co-culture and treated with temsirolimus plus ABT737 in co-culture. Samples were grouped based on mutation status: group I, unmutated samples; group II, FLT3-mutated samples. Difference in apoptosis between ABT737-treated samples in monoculture and co-culture and between ABT737-and temsirolimus plus ABT737-treated samples in co-culture was calculated using a two-tailed paired Student t test. Results are displayed in the bar graph on the right (mean ± standard error of the mean). Statistical significance was defined as p ≤ 0.05. (B) Box and whisker plots display difference in protein expression between untreated samples in groups I and II with and without stroma (left panel) and baseline protein expression of untreated samples in groups I and II in co-culture (right panel). Significance was calculated using a two-tailed unequal variance Student t test. Statistical significance was defined as p ≤ 0.05. Whiskers indicate the range from minimum to maximum values. The line in the middle of the box is plotted at the median.
